JP2021534740A5 - - Google Patents

Info

Publication number
JP2021534740A5
JP2021534740A5 JP2021507503A JP2021507503A JP2021534740A5 JP 2021534740 A5 JP2021534740 A5 JP 2021534740A5 JP 2021507503 A JP2021507503 A JP 2021507503A JP 2021507503 A JP2021507503 A JP 2021507503A JP 2021534740 A5 JP2021534740 A5 JP 2021534740A5
Authority
JP
Japan
Prior art keywords
genetically modified
modified hematopoietic
nucleic acid
nucleotide sequence
domain
Prior art date
Application number
JP2021507503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534740A (ja
JPWO2020037066A5 (https=
JP7456638B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/046550 external-priority patent/WO2020037066A1/en
Publication of JP2021534740A publication Critical patent/JP2021534740A/ja
Publication of JP2021534740A5 publication Critical patent/JP2021534740A5/ja
Publication of JPWO2020037066A5 publication Critical patent/JPWO2020037066A5/ja
Application granted granted Critical
Publication of JP7456638B2 publication Critical patent/JP7456638B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021507503A 2018-08-14 2019-08-14 クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用 Active JP7456638B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862718579P 2018-08-14 2018-08-14
US201862718491P 2018-08-14 2018-08-14
US62/718,491 2018-08-14
US62/718,579 2018-08-14
PCT/US2019/046550 WO2020037066A1 (en) 2018-08-14 2019-08-14 Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof

Publications (4)

Publication Number Publication Date
JP2021534740A JP2021534740A (ja) 2021-12-16
JP2021534740A5 true JP2021534740A5 (https=) 2022-08-22
JPWO2020037066A5 JPWO2020037066A5 (https=) 2022-08-22
JP7456638B2 JP7456638B2 (ja) 2024-03-27

Family

ID=69524868

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507503A Active JP7456638B2 (ja) 2018-08-14 2019-08-14 クレブス回路を調節するトランス代謝分子と組み合わせたキメラ抗原受容体ポリペプチド、及び、それらの治療的使用

Country Status (13)

Country Link
US (2) US12077785B2 (https=)
EP (1) EP3837353A4 (https=)
JP (1) JP7456638B2 (https=)
KR (1) KR20210045418A (https=)
CN (1) CN112840019B (https=)
AU (1) AU2019321540B2 (https=)
BR (1) BR112021001694A2 (https=)
CA (1) CA3108126A1 (https=)
IL (1) IL280322B2 (https=)
MX (1) MX2021001771A (https=)
SG (1) SG11202101284UA (https=)
WO (1) WO2020037066A1 (https=)
ZA (1) ZA202100993B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CA3182769A1 (en) * 2020-06-15 2021-12-23 Andrew P. Mazar Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (upar) for treatment of severe covid-19 disease
EP4192586A4 (en) * 2020-08-10 2024-10-16 Arizona Board of Regents on behalf of Arizona State University Metabolism-based chimeric antigen receptors and methods of treatment
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023049933A1 (en) 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
US20250000906A1 (en) 2021-11-16 2025-01-02 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients
EP4249588A1 (en) * 2022-03-22 2023-09-27 Universität Basel Vizerektorat Forschung Cellular therapy
WO2024015995A2 (en) * 2022-07-15 2024-01-18 Albert Einstein College Of Medicine Chimeric antigen receptors comprising a tmigd2 costimulatory domain and associated methods of using the same
US20260053924A1 (en) 2022-08-19 2026-02-26 Sotio Biotech Inc. Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof
WO2024040207A1 (en) 2022-08-19 2024-02-22 Sotio Biotech Inc. Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2026052052A1 (en) * 2024-09-06 2026-03-12 Jw Therapeutics R & D (Shanghai) Co., Ltd. Polypeptide for the treatment of diseases associated with gpc3

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
JP2752788B2 (ja) 1989-01-23 1998-05-18 カイロン コーポレイション 感染および過剰増殖障害の為の組換え療法
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
JP4041535B2 (ja) 1989-08-18 2008-01-30 オックスフォード バイオメディカ(ユーケー)リミテッド 標的細胞にベクター構造体を運搬する組換レトロウィルス
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
CA2168202A1 (en) 1993-07-30 1995-03-16 Joseph Dougherty Efficient gene transfer into primary lymphocytes
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5756910A (en) 1996-08-28 1998-05-26 Burgett, Inc. Method and apparatus for actuating solenoids in a player piano
ES2278399T3 (es) 1996-11-20 2007-08-01 Introgen Therapeutics, Inc. Metodo mejorado para la produccion y purificacion de vectores adenovirales.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1135495A2 (en) 1998-12-01 2001-09-26 Genentech, Inc. Secreted amd transmembrane polypeptides and nucleic acids encoding the same
US7052906B1 (en) 1999-04-16 2006-05-30 Celltech R & D Limited Synthetic transmembrane components
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CN1842540B (zh) 2004-07-09 2012-07-04 中外制药株式会社 抗-磷脂酰肌醇蛋白聚糖3抗体
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
EP2855698A4 (en) * 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
EP3057986B1 (en) 2013-10-17 2017-12-27 National University of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
JP2017529851A (ja) * 2014-09-26 2017-10-12 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 養子免疫療法のためのグリピカン−3特異的キメラ抗原レセプター
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
JP7115982B2 (ja) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド 癌の治療のための組成物及び方法
US11020429B2 (en) * 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
WO2017123808A1 (en) * 2016-01-15 2017-07-20 The J. David Gladstone Institutes Methods of treating disease by metabolic control of t-cell differentiation
EP3430036A4 (en) 2016-03-18 2019-08-14 Unum Therapeutics MODIFIED CHIMERIC RECEPTORS AND USES IN IMMUNOTHERAPY
US11377637B2 (en) 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
EP3573660A4 (en) 2017-01-30 2021-01-06 Unum Therapeutics Inc. IMPROVED ANTIBODY T-LYMPHOCYTE RECEPTOR CONSTRUCTIONS AND THEIR THERAPEUTIC USES
CA3104862A1 (en) 2018-07-03 2020-01-09 Sotio, LLC Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
WO2020028572A2 (en) * 2018-08-01 2020-02-06 Unum Therapeutics Inc. ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
WO2020037142A1 (en) * 2018-08-17 2020-02-20 Yale University Compositions and methods for high-throughput activation screening to boost t cell effector function
CA3118889A1 (en) * 2018-11-07 2020-05-14 Sotio, LLC Anti-gpc3 chimeric antigen receptors (cars) in combination with trans co-stimulatory molecules and therapeutic uses thereof
US20220142948A1 (en) * 2019-03-18 2022-05-12 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
WO2023049933A1 (en) * 2021-09-27 2023-03-30 Sotio Biotech Inc. Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
US20250000906A1 (en) * 2021-11-16 2025-01-02 Sotio Biotech Inc. Treatment of myxoid/round cell liposarcoma patients

Similar Documents

Publication Publication Date Title
JP2021534740A5 (https=)
JP2021536265A5 (https=)
JP2021529559A5 (https=)
US20240059754A1 (en) Chimeric antigen receptors and enhancement of anti-tumor activity
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
Nolan et al. Bypassing immunization: optimized design of “designer T cells” against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA
CN105384825B (zh) 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US20190023764A1 (en) Car having replicated binding motifs in a co-stimulatory domain
EP3169703B1 (en) Chimeric antigen receptor and its use
US20240342283A1 (en) ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors
CN109280086B (zh) 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体
JP2024023228A5 (https=)
BR112019017629A2 (pt) receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor
Pameijer et al. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor
JPWO2019173324A5 (https=)
JPWO2020010110A5 (https=)
CN105194661A (zh) 时空可调性抑制病理性靶细胞的系统
JPWO2020051493A5 (https=)
US12187776B2 (en) Pooling signaling and costimulatory domains in B7H6 chimeric antigen receptor
JPWO2020037066A5 (https=)
JPWO2022133169A5 (https=)
Vyas et al. Mono-and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
US20240277845A1 (en) Antibody-nkg2d ligand domain fusion protein
WO2021027785A1 (zh) 共表达趋化因子受体的免疫效应细胞
CN118510814A (zh) 一种嵌合抗原受体及其应用